These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 36779660)
21. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N JCO Precis Oncol; 2022 May; 6():e2200085. PubMed ID: 35613413 [TBL] [Abstract][Full Text] [Related]
22. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Diossy M; Reiniger L; Sztupinszki Z; Krzystanek M; Timms KM; Neff C; Solimeno C; Pruss D; Eklund AC; Tóth E; Kiss O; Rusz O; Cserni G; Zombori T; Székely B; Kulka J; Tímár J; Csabai I; Szallasi Z Ann Oncol; 2018 Sep; 29(9):1948-1954. PubMed ID: 29917049 [TBL] [Abstract][Full Text] [Related]
23. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629 [TBL] [Abstract][Full Text] [Related]
24. Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity. Korsholm LM; Kjeldsen M; Perino L; Mariani L; Nyvang GB; Kristensen E; Bagger FO; Mirza MR; Rossing M JCO Precis Oncol; 2024 Feb; 8():e2300483. PubMed ID: 38427930 [TBL] [Abstract][Full Text] [Related]
25. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124 [TBL] [Abstract][Full Text] [Related]
26. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Lau CH; Seow KM; Chen KH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700 [TBL] [Abstract][Full Text] [Related]
27. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency? Gourley C; Miller RE; Hollis RL; Ledermann JA Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232 [TBL] [Abstract][Full Text] [Related]
28. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
29. Biomarkers for Homologous Recombination Deficiency in Cancer. Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099 [TBL] [Abstract][Full Text] [Related]
30. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types. Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Ahmed RM; Denman M; Steele CD; Tarabichi M; Roy E; Davies LR; Manji J; Cristalli C; Scotlandi K; Pillay N; Strauss SJ; Mittnacht S Nat Commun; 2021 Dec; 12(1):7064. PubMed ID: 34862364 [TBL] [Abstract][Full Text] [Related]
32. Prediction of homologous recombination deficiency from cancer gene expression data. Kang J; Lee J; Lee A; Lee YS J Int Med Res; 2022 Nov; 50(11):3000605221133655. PubMed ID: 36380518 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. Lin C; Liu P; Shi C; Qiu L; Shang D; Lu Z; Tu Z; Liu H Fundam Clin Pharmacol; 2023 Apr; 37(2):194-214. PubMed ID: 36130021 [TBL] [Abstract][Full Text] [Related]
34. Homologous Recombination Repair Deficiency: An Overview for Pathologists. Doig KD; Fellowes AP; Fox SB Mod Pathol; 2023 Mar; 36(3):100049. PubMed ID: 36788098 [TBL] [Abstract][Full Text] [Related]
35. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415 [TBL] [Abstract][Full Text] [Related]
36. Development of Homologous Recombination Functional Assays for Targeting the DDR. Oswald AJ; Gourley C Cancer Treat Res; 2023; 186():43-70. PubMed ID: 37978130 [TBL] [Abstract][Full Text] [Related]